AD
Galderma will present data on Relfydess (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator designed with PEARL Technology – which further demonstrate its rapid onset and efficacy through 6 months in both moderate-to-severe frown lines (glabellar lines) and crow’s feet (lateral canthal lines)1-3
Dysport (AbobotulinumtoxinA) data demonstrating high levels of patient and practitioner satisfaction after treatment of frown lines will also be presented4,5
Galderma will also present a Masterclass on the science behind Relfydess, demonstrating how the company is shaping the future of neuromodulation
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The company will share data from five abstracts on two neuromodulators from its portfolio, Relfydess – the first and only ready-to-use liquid neuromodulator designed with PEARL Technology – and Dysport. Additionally, Galderma will be hosting a Relfydess Masterclass in which expert speakers will delve into the science and clinical data behind Relfydess.
|
“At TOXINS 2026, we will demonstrate our continued leadership in neuromodulation through updates on our leading portfolio, and an educational session on Relfydess, an innovative, science-backed neuromodulator that delivers advanced performance. As the only company with a portfolio of neuromodulators, we’re building on our heritage in the space by developing next-generation solutions that address the evolving expectations of both patients and practitioners.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA
|
|
